Look inside the book: Nursing 2025-2026 Drug Handbook

220 capecitabine

NURSING CONSIDERATIONS • Monitor patient for hypersensitivity re actions (anaphylactic reactions, anaphylac tic shock, bronchospasm, angioedema, stri dor). Discontinue drug immediately and treat emergently. • Monitor patient for signs of overt bleeding and symptoms of active bleeding. • Note that platelet function will normalize 1 hour after discontinuation of infusion. PATIENT TEACHING • Explain that drug is used to inhibit platelet function during PCI and that platelet function and clot formation normalize 1 hour after in fusion. • Warn patient of risk of bleeding; advise pa tient to immediately report signs and symp toms of bleeding (mental status changes, light-headedness, low BP, blood in stool or urine, bleeding from gums, joint pain and swelling, abnormal bruising, abdominal or chest pain). • Caution that hypersensitivity reactions may occur. Instruct patient to immediately report difficulty breathing, swelling of throat and lips, faintness, hives, or rash. capecitabine kap-ah-SEAT-ah-been Xeloda Therapeutic class: Antineoplastics Pharmacologic class: Pyrimidine analogues AVAILABLE FORMS Tablets : 150 mg; 500 mg INDICATIONS & DOSAGES Adjust-a-dose (for all indications): Round to nearest dose that gives a whole tablet; don’t cut tablets in half. For patients with CrCl of 30 to 50 mL/minute: Reduce starting dose to 75% of usual start ing dose PO b.i.d. Dosage for severe kidney impairment (CrCl less than 30 mL/minute) hasn’t been established. Refer to prescribing information for dosing of agents used in combination. Refer to manufacturer’s instructions for toxicity-related dosage adjustments. SAFETY ALERT!

➤ Advanced or metastatic breast cancer as a single agent if anthracycline- or taxane containing chemotherapy isn’t indicated or in combination with docetaxel after dis ease progression on prior anthracycline containing chemotherapy Adults: 1,000mg/m 2 or 1,250 mg/m 2 PO b.i.d. on days 1 to 14 of each 21-day cycle un til disease progression or unacceptable toxi city occurs. When used in combination with docetaxel, give docetaxel 75 mg/m 2 IVonday 1 of each cycle. Adjust-a-dose: Individualize dose based on patient risk factors and adverse reactions. ➤ Adjuvant treatment of stage III colon cancer as a single agent or as part of com bination chemotherapy with oxaliplatin containing regimen Adults: 1,250mg/m 2 PO b.i.d. as a single agent or 1,000 mg/m 2 PO b.id. as part of com bination chemotherapy on days 1 to 14 of each 21-day cycle for a maximum of 8 cy cles. When used in combination therapy, give oxaliplatin 130 mg/m 2 IV on day 1 of each cycle. ✷ NEW INDICATION: Perioperative treatment of locally advanced rectal cancer as part of chemoradiotherapy Adults: 825mg/m 2 PO b.i.d. with concomi tant radiation therapy or 1,250 mg/m 2 PO b.i.d. without concomitant radiation therapy. ✷ NEW INDICATION: Unresectable or meta static colorectal cancer as a single agent or as part of combination chemotherapy Adults: 1,250mg/m 2 PO b.i.d. on days 1 to 14 as a single agent or 1,000 mg/m 2 incom bination with oxaliplatin on days 1 to 14 of each 21-day cycle until disease progression or unacceptable toxicity occurs. When used in combination with oxaliplatin, give oxaliplatin 130mg/m 2 IV on day 1 of each cycle. ✷ NEW INDICATION: Unresectable or metastatic gastric, esophageal, or gastroe sophageal junction cancer as part of com bination chemotherapy Adults: 625mg/m 2 PO b.i.d. on days 1 to 21 of each 21-day cycle for a maximum of 8 cycles, in combination with platinum containing chemotherapy. Or, 850 mg/m 2 or 1,000mg/m 2 PO b.i.d. on days 1 to 14 of each 21-day cycle until disease progression or un acceptable toxicity occurs, in combination with oxaliplatin 130 mg/m 2 IV on day 1 of each cycle.

Copyright © 2025 Wolters Kluwer, Inc. Unauthorized reproduction of this content is prohibited.

Reactions in bold italics are life-threatening .